A major contributor to this article appears to have a close connection with its subject. (December 2017) (Learn how and when to remove this template message)
The Roskamp Institute, was co-founded by Robert and Diane Roskamp, and Fiona Crawford and Michael Mullan in Sarasota, Florida in 2003. It is a nonprofit biomedical research facility specializing neurological research including Alzheimer's disease, traumatic brain injury, Gulf War syndrome, and posttraumatic stress disorder. It also operates an onsite neurology clinic. The Institute is focused on finding the causes and treatments for neuropsychiatric and neurodegenerative diseases.
The Institute's lead researchers, Michael Mullan and Fiona Crawford, were members of a team of scientists who discovered the first genetic errors causing Alzheimer’s disease in 1991 in the APP gene in early onset familial cases. Mullan and Crawford also discovered the Swedish mutation which has been incorporated into transgenic mice which are widely used to understand the disease and test new treatments.
The Institute is particularly focused on translational research that can lead to novel drug or other therapeutic interventions in neurodegenerative disorders. In this regard, Institute scientists discovered that certain members of a class of drugs called dihydropyridines [DHPs] can lower the levels of amyloid beta in the brains of transgenic models of the disease and decided to take one of them, nilvadipine, forward into clinical trials for Alzheimer’s disease. This work was conducted by Archer Pharmaceuticals, a for-profit spin off of the Institute, headed by Mullan. In partnership with colleagues at Trinity College, Dublin lead by Brian Lawlor, Archer and Institute scientists conducted an open label phase I/II trial of nilvadipine in mild to moderate Alzheimer’s disease subjects. More recently, in collaboration with multiple partners at academic institutes in Europe, and again led by Lawlor, Archer and Roskamp Institute scientists partnered to conduct a phase III clinical trial of nilvadipine in mild to moderate Alzheimer’s disease.
The institute is currently housed in a 41,000 sq ft (3,800 m2) scientific research facility in Sarasota, Florida. The institute facility contains mass spectrometry, pathology, microscopy, certified GMO testing, and chemistry labs. The organization employs more than 50 scientists, technicians, clinicians, and other research staff.
The neurology clinic, headed by neurologist Andy Keegan, offers free memory screening as well as conducts various clinical trials simultaneously for neurological disorders.
- "Sarasota's Roskamp Institute Discovers New Class Of Drugs That Can Impact Alzheimer's Disease". Medical News Today. 26 January 2007.
- "Who We Are: Executive Leadership". roskampinstitute.org.
- Mullan, M.; Crawford, F.; Axelman, K.; Houlden, H.; Lilius, L.; Winblad, B.; Lannfelt, L. (August 1992). "A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid". Nature Genetics. 1 (5): 345–347. doi:10.1038/ng0892-345. ISSN 1061-4036. PMID 1302033.
- Lawlor, Brian; Kennelly, Sean; O'Dwyer, Sarah; Cregg, Fiona; Walsh, Cathal; Coen, Robert; Kenny, Rose Anne; Howard, Robert; Murphy, Caroline (2014-10-01). "NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease". BMJ Open. 4 (10): e006364. doi:10.1136/bmjopen-2014-006364. ISSN 2044-6055. PMC 4194801. PMID 25300460.
- Dublin, Trinity News and Events, Trinity College. "Clinical Trials for New Alzheimer's Disease Treatment Led by Trinity College Dublin Researchers to be Awarded European Commission 6 million Funding". www.tcd.ie. Retrieved 2017-10-10.